A Phase 1 Study of Anti-Human EGFR (Vectibix Sequence) Targeted EDVs Carrying the Cytotoxic Drug PNU-159682 (EGFR-VEDVsPNU) with Concurrent Non-Targeted EDVs Carrying an Immunomodulatory Adjuvant (EDVs40-mer) in Subjects with Advanced Solid Tumours who have No Curative Treatment Options

Trial Profile

A Phase 1 Study of Anti-Human EGFR (Vectibix Sequence) Targeted EDVs Carrying the Cytotoxic Drug PNU-159682 (EGFR-VEDVsPNU) with Concurrent Non-Targeted EDVs Carrying an Immunomodulatory Adjuvant (EDVs40-mer) in Subjects with Advanced Solid Tumours who have No Curative Treatment Options

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs PNU 159682 (Primary) ; Adjuvants
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Designer EDV / ENG8
  • Sponsors EnGeneIC
  • Most Recent Events

    • 08 Mar 2018 Status changed from suspended to recruiting.
    • 28 Feb 2018 Anticipated date last participant enrolled is 4 Feb 2019 as per Australian New Zealand Clinical Trials Registry
    • 28 Feb 2018 Planned number of patients changed from 30 to 20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top